The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.
Inclusion Criteria: * High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine * The use of effective contraception or abstinence for subjects of reproductive age * Written informed consent Exclusion Criteria: * Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria. * Actual severe depression * Allergy to one of the constituents * Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma * IMAO treatment discontinued less than 2 months or contra-indicated associated treatment